Matthew Cooper, PhD, DABT, MBA, is Chief Scientific Officer at Progenity.
Dr. Cooper was previously the CEO and Founder of Carmenta Bioscience before Progenity acquired the company in 2015. He is also a member of the Board of Directors for Avails Medical, NeoSeq, and the Preeclampsia Foundation. Dr. Cooper serves in advisory roles for SPARK (Stanford School of Medicine), StartX (Stanford start-up incubator), and Lean LaunchPad for the Life Sciences at UCSF. Prior to Carmenta, Dr. Cooper was founding Chief Scientific Officer at Syapse, a precision medicine software platform company, and spent over a decade in biomarker and drug development across the value chain at such companies as Biogen Idec and Roche.
Dr. Cooper's educational background includes dual MBAs from Columbia Business School (Finance) and the Berkeley Haas School of Business (Entrepreneurship). He also obtained a PhD in Toxicology (University of Kentucky, College of Medicine) and BS in Chemistry (University of Tulsa, College of Engineering). He is board certified in toxicology (Diplomat of the American Board of Toxicology) and has earned a Certificate of Entrepreneurship from the Berkeley Haas School of Business. Matt is also an avid foodie and wine collector. When not at work, you can find him traveling the world in search of his next best meal.